Fialuridine

Drugbox
IUPAC_name = 1- [(2"R",3"S",4"R",5"R")-3-Fluoro-4-hydroxy-5-(hydroxymethyl)- 2-tetrahydrofuranyl] -5-iodopyrimidine-2,4-dione

---

CAS_number =
ATC_prefix =
ATC_suffix =
PubChem = 50313
DrugBank =
C=9|H=10|F=1|I=1|N=2|O=5
molecular_weight = 372.09 g/mol
synonyms = 2′-Fluoro-5-iodouracil
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Fialuridine, or 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU), is a nucleoside analogue . It was originally designed as a therapy for hepatitis B virus infection. Unexpected toxicity lead to the death of 5 out of 15 patients in a clinical study at the NIH from fulminant liver failure. This toxicity was unusual in that it was not predicted by animal studies.

References

*cite journal |author=McKenzie R, Fried MW, Sallie R, "et al" |title=Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B |journal=N. Engl. J. Med. |volume=333 |issue=17 |pages=1099–105 |year=1995 |pmid=7565947 |doi=

* [http://books.nap.edu/openbook.php?record_id=4887&page=R1 Review of the Fialuridine (FIAU) Clinical Trials] , Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials, Division of Health Sciences Policy INSTITUTE OF MEDICINE Frederick J. Manning and Morton Swartz, Editors NATIONAL ACADEMY PRESS Washington, D.C.1995